Bromocriptine treatment in a murine Parkinson's model: ultrastructural evaluation after dopaminergic deafferentation.
The objective of this article was to identify the effects of bromocriptine on the ultrastructure of the caudate nucleus in rats with a 6-hydroxidopamine (6-OHDA) unilateral lesion of the substantia nigra pars compacta. Eighteen Wistar male rats were stereotactically lesioned with 6-OHDA (n=12), or sham lesioned (n=6). Two days after rotational behavior was tested, and 2 days later, 6 rats were treated with 0.3 mg/Kg bromocriptine orally for a month and 6 rats were kept for the same time without treatment. The neuropile of the sham operated and bromocriptine-treated rats was well preserved contrary to the non-bromocriptine-treated rats. Also, it was found that there was a significant difference in the number of synaptic endings with edema in caudate of bromocriptine-treated rats compared with non-treated rats; however, the size of the synaptic endings were different to those found in the sham lesioned rats. Also, as in the sham lesioned group, the bromocriptines showed more synaptic contacts with dendritic spines contrasting to the non-treated group. The results suggest that bromocriptine possesses antioxidant properties because it decreased the ultrastructural alterations after 6-OHDA lesion.
Avila-Costa
María Rosa
MR
Department of Neuroscience, National University of Mexico, Iztacala, Mexico. nigraizo@servidor.unam.mx
Colín-Barenque
Laura
L
Montiel-Flores
Enrique
E
Aley-Medina
Patricia
P
Valdez
Ana Luisa Gutiérrez
AL
Librado
José Luis Ordóñez
JL
Martínez
Erick Flores
EF
Martínez
Verónica Anaya
VA
Mussali-Galante
Patricia
P
Fortoul
Teresa I
TI
D000818:Animals; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D001971:Bromocriptine / Q000627:therapeutic use*; D002421:Caudate Nucleus / Q000378:metabolism* / Q000648:ultrastructure*; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism*; D008297:Male; D009045:Motor Endplate / Q000378:metabolism / Q000648:ultrastructure; D018384:Oxidative Stress / Q000502:physiology; D010300:Parkinson Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar
D000978:Antiparkinson Agents; D001971:Bromocriptine; D004298:Dopamine